**TABLE 1** Baseline Characteristics - Demographic characteristic

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variables  N (%) | Overall population | | | | Propensity-matched population | | | |
| Low-LDL-C  (N = 1202) | | High-LDL-C  (N = 593) | p value | Low-LDL-C  (N = 443) | | High-LDL-C  (N = 443) | p value |
| Age (yrs) | 66.3±10.5 | | 63.0±10.2 | <0.001\* | 62.3±10.5 | | 63.7±10.5 | 0.996 |
| Male | 909/1200(75.8) | | 390/590(66.1) | <0.001\* | 297/443(67.0) | | 307/443(69.3) | 0.471 |
| Body-mass index | 24.6±3.4 | | 24.9±3.5 | 0.208 | 25.6±3.2 | | 24.6±3.0 | 0.326 |
| Diabetes | 272/1176(23.1) | | 129/585(22.1) | 0.661 | 98/443(22.1) | | 98/443(22.1) | 1.000 |
| Hypertension | 781/1175(66.5) | | 346/585(59.1) | 0.003\* | 257/443(58.0) | | 266/443(60.0) | 0.539 |
| Congestive heart failure | 29/1116(2.6) | | 22/555(4.0) | 0.126 | 10/408(2.5) | | 14/409(3.4) | 0.411 |
| ACS | 488/1175(41.5) | | 272/580(46.9) | 0.033\* | 175/443(39.5) | | 181/443(40.9) | 0.681 |
| Previous cerebrovascular disease | 107/1176(9.1) | | 44/585(7.5) | 0.266 | 37/443(8.4) | | 30/443(6.8) | 0.374 |
| Current smoker | 337/1174(28.7) | | 186/583(31.9) | 0.167 | 119/443(26.9) | | 134/442(30.3) | 0.255 |
| Current alcohol consumption | | 241/1173(20.5) | 133/582(22.9) | 0.267 | | 87/442(19.7) | 105/442(23.8） | 0.142 |

Values are mean ± SD, n (%), or n/N (%). ACS = acute coronary syndrome.

\* the p < 0.05.

**TABLE 2** Baseline Characteristics - Laboratory ﬁndings

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | Overall population | |  | Propensity-matched population | | |
| Low-LDL-C  (N = 1202) | High-LDL-C  (N = 593) | p value | Low-LDL-C  (N = 443) | High-LDL-C  (N = 443) | p value |
| LDL-C —mmol/L† | | | | | | |
|  | 1.85 (1.49-2.21) | 3.15(2.73-3.57) | < 0.001\* | 1.84(1.57-2.12) | 3.2(2.76-3.64) | < 0.001\* |
| HDL-C —mmol/L† | | | | | | |
|  | 0.95(0.77-1.14) | 1.02(0.85-1.20) | < 0.001\* | 0.98(0.84-1.12) | 1.04(0.90-1.18) | 0.216 |
| TG—mmol/L† | | | | | | |
|  | 1.28(0.85-1.72) | 1.55(1.12-1.98) | < 0.001\* | 1.44(0.79-2.09) | 1.53(1.10-1.97) | < 0.001\* |
| eGFR (SD) — mL/min/1.73 m2‡† | | | | | | |
|  | 71.86(56.03-87.69) | 77.11(58.83-95.39) | < 0.001\* | 75.62(60.48-90.76) | 79.83(60.44-99.21) | 0.362 |

Abbreviations: LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; eGFR, estimated glomerular ﬁltration rate.

†Median (Interquartile range).

‡ eGFR is estimated by using the Modiﬁcation of Diet in Renal Disease equation.

\* the p < 0.050.

**TABLE 3** Baseline Characteristics - Coronary angiographic and procedural ﬁndings

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables  N (%) | Overall population | |  | Propensity-matched population | | |
| Low-LDL-C  (N = 1202) | High-LDL-C  (N = 593) | p value | Low-LDL-C  (N = 443) | High-LDL-C  (N = 443) | p value |
| Multivessel coronary disease | 186/1147(16.2) | 108/558(19.4) | 0.107 | 91/443(20.5) | 91/443(20.5) | 1.000 |
| Culprit vessel | | | | | | |
| Left main | 104/1147(9.1) | 49/558(8.8) | 0.846 | 42/443(9.5) | 39/443(8.8) | 0.727 |
| Left anterior descending | 718/1147(62.6) | 344/558(61.6) | 0.704 | 271/443(61.2) | 278/443(62.8) | 0.628 |
| Left circumﬂex | 220/1147(19.2) | 134/558(24.0) | 0.021\* | 114/443(25.7) | 107/443(24.2) | 0.587 |
| Right | 278/1147(24.2) | 136/558(24.4) | 0.951 | 106/443(23.9) | 104/443(23.5) | 0.874 |
| Lesion type B2 or C | 1067/1108(96.3) | 502/529(94.9) | 0.183 | 404/430(94.0) | 398/420(94.8) | 0.610 |
| Calcification lesion | 191/1111(17.2) | 95/534(17.8) | 0.764 | 81/431(18.8) | 75/425(17.6) | 0.664 |
| CTO | 52/1111(4.7) | 37/536(6.9) | 0.062 | 17/431(3.9) | 27/424(6.4) | 0.109 |
| Primary PCI | 251/1147(21.9) | 93/558(16.7) | 0.012\* | 80/443(18.1) | 72/443(16.3) | 0.476 |
| Stent length (mm) | 39±22 | 40±23 | 0.209 | 53±28 | 55±25 | 0.110 |
| Stent diameter≥ 2.5 mm | 934/1147(81.4) | 457/558(81.9) | 0.814 | 352/443(79.5) | 362/443(81.7) | 0.396 |
| Stent number | 2.3±1.0 | 2.2±0.8 | 0.498 | 2.2±0.9 | 2.2±0.9 | 0.762 |

Abbreviations: CTO, chronic total occlusion.

\* the p < 0.050.

**TABLE 4** Baseline Characteristics – Medications

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables  N (%) | Overall population | |  | Propensity-matched population | | |
| Low-LDL-C  (N = 1202) | High-LDL-C  (N = 593) | p value | Low-LDL-C  (N = 443) | High-LDL-C  (N = 443) | p value |
| Medications | | | | | | |
| Antiplatelet drug | | | | | | |
| Aspirin | 1163/1202(96.8) | 581/591(98.3) | 0.058 | 432/443(97.5) | 436/443(98.4) | 0.341 |
| Clopidogrel | 1079/1202(89.8) | 535/591(90.5) | 0.615 | 408/443(92.1) | 403/443(91.0) | 0.546 |
| Ticagrelor | 6/1202(0.5) | 4/591(0.7) | 0.738 | 0/443(0.0) | 3/443(0.7) | 0.083 |
| Cilostazol | 32/1202(2.7) | 8/591(1.4) | 0.078 | 10/443(2.3) | 6/443(1.4) | 0.313 |
| Warfarin | 15/1202(1.2) | 8/591(1.4) | 0.852 | 9/443(2.0) | 5/443(1.1) | 0.281 |
| Lipid-lowering drug | | | | | | |
| Statin | 1186/1202(98.7) | 582/591(98.5) | 0.745 | 439/443(99.1) | 437/443(98.6) | 0.525 |
| Fibrates | 8/1202(0.7) | 2/591(0.3) | 0.382 | 4/443(0.9) | 2/443(0.5) | 0.413 |
| Ezetimibe | 93/1202(7.7) | 147/591(24.9) | <0.001\* | 71/443(16.0) | 79/443(17.8) | 0.474 |
| ACEI or ARB | 715/1202(59.5) | 352/591(59.6) | 0.975 | 249/443(56.2) | 256/443(57.8) | 0.635 |
| Beta-blocker | 671/1202(55.8) | 303/591(51.3) | 0.069 | 230/443(51.9) | 219/443(49.4) | 0.460 |
| CCB | 302/1202(25.1) | 151/591(25.5) | 0.846 | 96/443(21.7) | 117/443(26.4) | 0.099 |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CCB, Dihydropyridine calcium-channel blocker.

\* the p < 0.050.

**TABLE 5** LDL-C levels (mmol/L) at admission and follow-up.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | Overall population | |  | Propensity-matched population | | |
| Low-LDL-C  (N = 1202) | High-LDL-C  (N = 593) | p value | Low-LDL-C  (N = 443) | High-LDL-C  (N = 443) | p value |
| LDL cholesterol — mmol/L | | | | | | |
| At admission† | 1.85 (1.49-2.21) | 3.15(2.73-3.57) | <0.001\* | 1.84(1.57-2.12) | 3.2(2.76-3.64) | <0.001\* |
| Follow-up† | 1.46(1.14-1.79) | 1.89(1.32-2.46) | <0.001\* | 1.45(1.07-1.82) | 1.78(1.15-2.41) | <0.001\* |
| Difference | 0.39 | 1.26 |  | 0.39 | 1.42 |  |
| Reduction (%) | 21.1 | 40 |  | 21.2 | 44.3 |  |
| p-Value | <0.001\* | <0.001\* |  | <0.001\* | <0.001\* |  |
| Patients reach the treatment LDL-C goal (< 1.8mmol/L)— no./total no (%) | | | | | | |
|  | 912/1202(75.9) | 275/591(46.5) | <0.001\* | 327/443(73.8) | 219/442(49.5) | <0.001\* |

†Median (Interquartile range).

\* the p < 0.050.

**TABLE 6** Clinical outcomes in the study, According to the different baseline LDL-C lever.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Low-LDL-C  (N = 1202) | | High-LDL-C  (N = 593) | Unadjusted | | Adjusted 1§ | |
| HR (95% CI) | p | HR (95% CI) | p |
| 1. Overall population(N=1795) | | | | | | |  |
| Primary end point | | | | | | | |
| MACE | | 126(13.0) | 76(16.1) | 1.202(0.904-1.598) | 0.205 | 1.009(0.701-1.452) | 0.960 |
| Secondary end points | | | | | | | |
| Cardiac death, MI, or Revascularization | | 111(11.8) | 71(15.2) | 1.281(0.951-1.725) | 0.103 | 1.051(0.718-1.538) | 0.800 |
| Cardiac death or MI | | 4(0.4) | 9(1.8) | 4.509(1.388-14.644) | 0.012\* | 10.300(1.046-101.461) | 0.046\* |
| All-cause death | | 8(0.7) | 12(2.4) | 3.019(1.234-7.387) | 0.015\* | 4.030(1.088-14.934) | 0.037\* |
| Cardiac death | | 3(0.3) | 8(1.6) | 5.347(1.418-20.156) | 0.013\* | 137.729(0.845-2.253×104) | 0.058 |
| MI | | 1(0.1) | 1(0.2) | 1.984(0.124-31.727) | 0.628 | 0.279(0.000-8.350×1045) | 0.981 |
| Revascularization | | 108(11.6) | 63(13.5) | 1.158(0.800-1.580) | 0.355 | 0.975(0.659-1.443) | 0.900 |
| Any nonfatal stroke | | 12(1.2) | 3(0.5) | 0.498(0.141-1.765) | 0.280 | 0.712(0.169-3.001) | 0.643 |
| Ischemic stroke | | 10(1.0) | 3(0.5) | 0.597(0.164-2.169) | 0.433 | 0.756(0.172-3.311) | 0.710 |
| Hemorrhagic stroke | | 2(0.2) | 0(0.0) | 0.026(0.000-5.988×103) | 0.563 | 0.000(0.000-5.533×10237) | 0.978 |
|  | Low-LDL-C  (N = 443) | | High-LDL-C  (N = 443) | Unadjusted | | Adjusted 2 Φ | |
| HR (95% CI) | p | HR (95% CI) | p |
| B. Propensity-matched population(N=886) | | | | | | | |
| Primary end point | | |  |  |  |  |  |
| MACE | | 51(13.9) | 52(15.1) | 1.032(0.702-1.519) | 0.872 | 0.981(0.656-1.468) | 0.926 |
| Secondary end points | |  | |  |  |  |  |
| Cardiac death, MI, or Revascularization | | 46(12.7) | 48(14.1) | 1.061(0.708-1.590) | 0.775 | 1.015(0.665-1.548) | 0.946 |
| Cardiac death or MI | | 0(0) | 4(1.3) | 65.957(0.021-2.050×105) | 0.045\* | 3.836\*107(0-1.734×10132) | 0.905 |
| All-cause death | | 1(0.2) | 7(2.1) | 7.156(0.880-58.180) | 0.031\* | 6.887(0.748-63.371) | 0.088 |
| Cardiac death | | 0(0) | 4(1.3) | 65.957(0.021-2.050×105) | 0.045\* | 3.836\*107(0-1.734×10132) | 0.905 |
| MI | | 0(0) | 0(0) | 0 | 0 | 0 | 0 |
| Revascularization | | 46(12.7) | 44(12.8) | 0.967(0.640-1.462) | 0.873 | 0.926(0.602-1.425) | 0.727 |
| Any nonfatal stroke | | 5(1.6) | 3(0.7) | 0.597(0.143-2.499) | 0.480 | 0.520(0.117-2.300) | 0.389 |
| Ischemic stroke | | 5(1.6) | 3(0.7) | 0.597(0.143-2.499) | 0.480 | 0.520(0.117-2.300) | 0.389 |
| Hemorrhagic stroke | | 0(0) | 0(0) | 0 | 0 | 0 | 0 |

The cumulative incidences of clinical outcomes are presented as Kaplan-Meier estimates during the median follow-up of 20.2 months (interquartile range: 14.2 to 26.4 months). The number of patients with speciﬁc event is also presented; p values are for adjusted hazard ratio (HR) and 95% conﬁdence interval (CI). Multivariable-adjusted Cox proportional hazard model analysis was performed using covariates.

§ Adjusted 1: The models were included age, gender, hypertension, current smoker, ACS, eGFR, left anterior descending, left circumﬂex, right coronary artery, stent length, primary PCI, coronary calcification, clopidogrel, warfarin, statin, fibrates, ezetimibe and LDL-C level during follow-up as covariates.

Φ Adjusted 2: The models were included triglyceride, ACS, multivessel coronary disease, left anterior descending, right coronary artery, stent length, statin, fibrates, ezetimibe and LDL-C level during follow-up as covariates.

\* the p < 0.05.